These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
509 related articles for article (PubMed ID: 38977835)
1. Cancer organoids 2.0: modelling the complexity of the tumour immune microenvironment. Polak R; Zhang ET; Kuo CJ Nat Rev Cancer; 2024 Aug; 24(8):523-539. PubMed ID: 38977835 [TBL] [Abstract][Full Text] [Related]
2. Organoids: new frontiers in tumor immune microenvironment research. Yang Y; Cui J; Kong Y; Hou Y; Ma C Front Immunol; 2024; 15():1422031. PubMed ID: 39136020 [TBL] [Abstract][Full Text] [Related]
3. Organoid Models of Tumor Immunology. Yuki K; Cheng N; Nakano M; Kuo CJ Trends Immunol; 2020 Aug; 41(8):652-664. PubMed ID: 32654925 [TBL] [Abstract][Full Text] [Related]
4. Taking a Full Snapshot of Cancer Biology: Deciphering the Tumor Microenvironment for Effective Cancer Therapy in the Oncology Clinic. Dzobo K OMICS; 2020 Apr; 24(4):175-179. PubMed ID: 32176591 [TBL] [Abstract][Full Text] [Related]
5. Organoids as an Enabler of Precision Immuno-Oncology. Zhao J; Fong A; Seow SV; Toh HC Cells; 2023 Apr; 12(8):. PubMed ID: 37190074 [TBL] [Abstract][Full Text] [Related]
6. Patient-Derived Organoids for Precision Cancer Immunotherapy. Grönholm M; Feodoroff M; Antignani G; Martins B; Hamdan F; Cerullo V Cancer Res; 2021 Jun; 81(12):3149-3155. PubMed ID: 33687948 [TBL] [Abstract][Full Text] [Related]
7. Preclinical tumor organoid models in personalized cancer therapy: Not everyone fits the mold. Hu LF; Yang X; Lan HR; Fang XL; Chen XY; Jin KT Exp Cell Res; 2021 Nov; 408(2):112858. PubMed ID: 34600901 [TBL] [Abstract][Full Text] [Related]
8. Reconstructing the tumor architecture into organoids. Luo Z; Zhou X; Mandal K; He N; Wennerberg W; Qu M; Jiang X; Sun W; Khademhosseini A Adv Drug Deliv Rev; 2021 Sep; 176():113839. PubMed ID: 34153370 [TBL] [Abstract][Full Text] [Related]
9. Unveiling the functional roles of patient-derived tumour organoids in assessing the tumour microenvironment and immunotherapy. Chen D; Xu L; Xuan M; Chu Q; Xue C Clin Transl Med; 2024 Sep; 14(9):e1802. PubMed ID: 39245957 [TBL] [Abstract][Full Text] [Related]
10. From Cancer to Immune Organoids: Innovative Preclinical Models to Dissect the Crosstalk between Cancer Cells and the Tumor Microenvironment. Picca F; Giannotta C; Tao J; Giordanengo L; Munir HMW; Botta V; Merlini A; Mogavero A; Garbo E; Poletto S; Bironzo P; Doronzo G; Novello S; Taulli R; Bersani F Int J Mol Sci; 2024 Oct; 25(19):. PubMed ID: 39409152 [TBL] [Abstract][Full Text] [Related]
11. Immunotherapy discovery on tumor organoid-on-a-chip platforms that recapitulate the tumor microenvironment. Zhang J; Tavakoli H; Ma L; Li X; Han L; Li X Adv Drug Deliv Rev; 2022 Aug; 187():114365. PubMed ID: 35667465 [TBL] [Abstract][Full Text] [Related]
12. Deciphering the performance of macrophages in tumour microenvironment: a call for precision immunotherapy. Toledo B; Zhu Chen L; Paniagua-Sancho M; Marchal JA; Perán M; Giovannetti E J Hematol Oncol; 2024 Jun; 17(1):44. PubMed ID: 38863020 [TBL] [Abstract][Full Text] [Related]
13. Immune organoids: from tumor modeling to precision oncology. Dao V; Yuki K; Lo YH; Nakano M; Kuo CJ Trends Cancer; 2022 Oct; 8(10):870-880. PubMed ID: 35773148 [TBL] [Abstract][Full Text] [Related]
14. Breast cancer organoids and their applications for precision cancer immunotherapy. Guan D; Liu X; Shi Q; He B; Zheng C; Meng X World J Surg Oncol; 2023 Oct; 21(1):343. PubMed ID: 37884976 [TBL] [Abstract][Full Text] [Related]
15. Organoid Modeling of the Tumor Immune Microenvironment. Neal JT; Li X; Zhu J; Giangarra V; Grzeskowiak CL; Ju J; Liu IH; Chiou SH; Salahudeen AA; Smith AR; Deutsch BC; Liao L; Zemek AJ; Zhao F; Karlsson K; Schultz LM; Metzner TJ; Nadauld LD; Tseng YY; Alkhairy S; Oh C; Keskula P; Mendoza-Villanueva D; De La Vega FM; Kunz PL; Liao JC; Leppert JT; Sunwoo JB; Sabatti C; Boehm JS; Hahn WC; Zheng GXY; Davis MM; Kuo CJ Cell; 2018 Dec; 175(7):1972-1988.e16. PubMed ID: 30550791 [TBL] [Abstract][Full Text] [Related]
16. 3D Tumor Models and Their Use for the Testing of Immunotherapies. Boucherit N; Gorvel L; Olive D Front Immunol; 2020; 11():603640. PubMed ID: 33362787 [TBL] [Abstract][Full Text] [Related]
17. The use of organoids in creating immune microenvironments and treating gynecological tumors. Zhou LF; Liao HY; Han Y; Zhao Y J Transl Med; 2024 Sep; 22(1):856. PubMed ID: 39313812 [TBL] [Abstract][Full Text] [Related]
18. 3D bioprinted tumor model: a prompt and convenient platform for overcoming immunotherapy resistance by recapitulating the tumor microenvironment. Zhang Z; Chen X; Gao S; Fang X; Ren S Cell Oncol (Dordr); 2024 Aug; 47(4):1113-1126. PubMed ID: 38520648 [TBL] [Abstract][Full Text] [Related]
19. Tumour organoids and assembloids: Patient-derived cancer avatars for immunotherapy. Mei J; Liu X; Tian HX; Chen Y; Cao Y; Zeng J; Liu YC; Chen Y; Gao Y; Yin JY; Wang PY Clin Transl Med; 2024 Apr; 14(4):e1656. PubMed ID: 38664597 [TBL] [Abstract][Full Text] [Related]
20. Organoid Models for Precision Cancer Immunotherapy. Sun CP; Lan HR; Fang XL; Yang XY; Jin KT Front Immunol; 2022; 13():770465. PubMed ID: 35450073 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]